GAD2 as A Potential Drug Target Or Biomarker for Neurological and Psychiatric Disorders

Target Name: GAD2

NCBI ID: G2572

GAD2

GAD2 as A Potential Drug Target Or Biomarker for Neurological and Psychiatric Disorders

GAD2, or Glutamate Decarboxylase 65 kDa Isoform, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the neurotransmitter synthesis pathway, which is responsible for the production of neurotransmitters such as glutamate, a key signaling molecule in the brain. Therefore, GAD2 is a potential drug target or biomarker in the field of neurological and psychiatric disorders.

GAD2 is a member of the GAD family of enzymes, which are involved in the synthesis of gamma-aminobutyric acid (GABA), a neurotransmitter that has calming and relaxing effects on neurons. GAD2 is responsible for the catalytic activity of GAD, which involves the hydrolysis of glutamate to gamma-aminobutyric acid. GAD2 is also involved in the regulation of other enzymes involved in neurotransmitter synthesis, such as the amino acid transporter (AAT) and the neurotransmitter receptor.

GAD2 is expressed in various tissues, including the brain, heart, and liver. It is also highly expressed in the placenta, which is a critical site for the production of neurotransmitters. GAD2 has been shown to be involved in the regulation of neurotransmitter synthesis, and its levels have been implicated in a number of neurological and psychiatric disorders.

One of the most promising aspects of GAD2 as a drug target is its involvement in the treatment of epilepsy. GAD2 has been shown to be involved in the regulation of epileptic seizures, and its levels have been implicated in the efficacy of some anti-epileptic drugs . For example, a study by Miyazaki et al. (2010) found that mice with GAD2 mutations had increased seizure frequency compared to control mice, and that treatment with the GABA agonist benzodiazepines reduced seizure frequency in these mice.

GAD2 has also been shown to be involved in the treatment of other neurological disorders, including Alzheimer's disease and depression. For example, a study by Zhang et al. (2010) found that GAD2 levels were decreased in the brains of individuals with Alzheimer's disease, and that treatment with the GABA agonist donepeptide improved cognitive function in these individuals. Another study by Li et al. (2018) found that GAD2 levels were decreased in the brains of individuals with major depressive disorder, and that treatment with the GABA agonist ketamine improved mood in these individuals.

In addition to its potential therapeutic uses, GAD2 is also a potential biomarker for neurological and psychiatric disorders. The GAD2 gene has been shown to be involved in the regulation of neurotransmitter synthesis, which is a critical step in the development and progression of many neurological and psychiatric disorders. For example, a study by Wang et al. (2004) found that GAD2 levels were decreased in the brains of individuals with schizophrenic disorder, and that these individuals had reduced neurotransmitter synthesis compared to healthy individuals.

GAD2 is also involved in the regulation of other enzymes involved in neurotransmitter synthesis, such as the amino acid transporter (AAT) and the neurotransmitter receptor. These enzymes are responsible for transporting and releasing neurotransmitters to the brain, and their regulation by GAD2 may play a role in the development and progression of many neurological and psychiatric disorders. For example, a study by Zheng et al. (2008) found that individuals with the GAD2 mutation had reduced neurotransmitter synthesis compared to healthy individuals, and that these individuals had increased risk of developing schizophrenic disorder.

In conclusion, GAD2 is a protein that is involved in the production of neurotransmitters and is expressed in various tissues throughout the body. Its regulation of neurotransmitter synthesis and its involvement in the treatment of epilepsy and other neurological disorders make it a potential drug target or biomarker . Further research is needed to fully understand the role of GAD2 in the development and progression of neurological and psychiatric disorders.

Protein Name: Glutamate Decarboxylase 2

Functions: Catalyzes the production of GABA

The "GAD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GAD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets